Acute Treatment with XMetA Activates Hepatic Insulin Receptors and Lowers Blood Glucose in Normal Mice

Journal of Cellular Biochemistry

Volumn 116, Issue 9, 2015, Pages 2109-2119

  Bedinger, Daniel H ^a,b   Kieffer, Dorothy A ^b   Goldfine, Ira D ^a   Roell, Marina K ^a   Adams, Sean H ^b,c  

^a XOMA Corporation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

CHO CELLS; DIABETES; INSULIN ANALOG; INSULIN RECEPTOR; LIVER; PARTIAL ALLOSTERIC AGONIST

Indexed keywords

3 HYDROXYBUTYRIC ACID; FAT; FATTY ACID; GLYCEROL; HUMAN MONOCLONAL ANTIBODY; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY XMETA; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; INSULIN BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; ADIPOSE TISSUE; AGONISTS; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MUSCLE; PHOSPHORYLATION;

MUS;

3-HYDROXYBUTYRIC ACID; ADIPOSE TISSUE; ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; CHO CELLS; CRICETULUS; HUMANS; INJECTIONS, INTRAVENOUS; INSULIN; LIVER; MALE; MICE; MUSCLES; ORGAN SPECIFICITY; PHOSPHORYLATION; RECEPTOR, INSULIN;

EID: 84937468623     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25168     Document Type: Article

References (40)

1. Bedinger DH, Goldfine ID, Corbin JA, Roell MK, Adams SH,. 2015. Differential pathway coupling of the activated insulin receptor drives signaling selectivity by XMetA, an allosteric partial agonist antibody. J Pharmacol Exp Ther. 353 (1): 35-43.
2. Bhaskar V, Goldfine ID, Bedinger DH, Lau A, Kuan HF, Gross LM, Handa M, Maddux BA, Watson SR, Zhu S, Narasimha AJ, Levy R, Webster L, Wijesuriya SD, Liu N, Wu X, Chemla-Vogel D, Tran C, Lee SR, Wong S, Wilcock D, White ML, Corbin JA,. 2012. A fully human, allosteric monoclonal antibody that activates the insulin receptor and improves glycemic control. Diabetes 61: 1263-1271.
3. Bhaskar V, Lau A, Goldfine ID, Narasimha AJ, Gross LM, Wong S, Cheung B, White ML, Corbin JA,. 2013. XMetA, an allosteric monoclonal antibody to the insulin receptor, improves glycaemic control in mice with diet-induced obesity. Diabetes Obes Metab 15: 272-275.
4. Bluher M, Patti ME, Gesta S, Kahn BB, Kahn CR,. 2004. Intrinsic heterogeneity in adipose tissue of fat-specific insulin receptor knock-out mice is associated with differences in patterns of gene expression. J Biol Chem 279: 31891-31901.
5. Brown PM, Tompkins CV, Juul S, Sonksen PH,. 1978. Mechanism of action of insulin in diabetic patients: A dose-related effect on glucose production and utilisation. Br Med J 1: 1239-1242.
6. Cahill GF, Jr., 2006. Fuel metabolism in starvation. Annu Rev Nutr 26: 1-22.
7. Camu F,. 1975. Hepatic balances of glucose and insulin in response to physiological increments of endogenous insulin during glucose infusions in dogs. Eur J Clin Invest 5: 101-108.
8. Chap Z, Ishida T, Chou J, Hartley CJ, Entman ML, Brandenburg D, Jones RH, Field JB,. 1987. First-pass hepatic extraction and metabolic effects of insulin and insulin analogues. Am J Physiol 252: E209-217.
9. Cherrington AD, Edgerton D, Sindelar DK,. 1998. The direct and indirect effects of insulin on hepatic glucose production in vivo. Diabetologia 41: 987-996.
10. Fanelli C, Calderone S, Epifano L, De Vincenzo A, Modarelli F, Pampanelli S, Perriello G, De Feo P, Brunetti P, Gerich JE, et al., 1993. Demonstration of a critical role for free fatty acids in mediating counterregulatory stimulation of gluconeogenesis and suppression of glucose utilization in humans. J Clin Invest 92: 1617-1622.
11. Garg A, Balthasar JP,. 2007. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34: 687-709.
12. Goldstein BJ, Dudley AL,. 1990. The rat insulin receptor: Primary structure and conservation of tissue-specific alternative messenger RNA splicing. Mol Endocrinol 4: 235-244.
13. Keller U, Chiasson JL, Liljenquist JE, Cherrington AD, Jennings AS, Crofford OS,. 1977. The roles of insulin, glucagon, and free fatty acids in the regulation of ketogenesis in dogs. Diabetes 26: 1040-1051.
14. Lobo ED, Hansen RJ, Balthasar JP,. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645-2668.
15. Madsbad S,. 2014. LY2605541-A preferential hepato-specific insulin analogue. Diabetes 63: 390-392.
16. McGarry JD,. 1992. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258: 766-770.
17. McGarry JD, Foster DW,. 1980. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 49: 395-420.
18. Miles PD, Levisetti M, Reichart D, Khoursheed M, Moossa AR, Olefsky JM,. 1995. Kinetics of insulin action in vivo. Identification of rate-limiting steps. Diabetes 44: 947-953.
19. Mittelman SD, Fu YY, Rebrin K, Steil G, Bergman RN,. 1997. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. J Clin Invest 100: 3121-3130.
20. Moller DE, Yokota A, Caro JF, Flier JS,. 1989. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 3: 1263-1269.
21. Moore MC, Smith MS, Sinha VP, Beals JM, Michael MD, Jacober SJ, Cherrington AD,. 2014. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes 63: 494-504.
22. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA,. 1990. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 9: 2409-2413.
23. Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF, Jr., 1967. Brain metabolism during fasting. J Clin Invest 46: 1589-1595.
24. Randle PJ, Garland PB, Newsholme EA, Hales CN,. 1965. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann N Y Acad Sci 131: 324-333.
25. Rizza RA, Mandarino LJ, Gerich JE,. 1981. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240: E630-639.
26. Serrano R, Villar M, Martinez C, Carrascosa JM, Gallardo N, Andres A,. 2005. Differential gene expression of insulin receptor isoforms A and B and insulin receptor substrates 1, 2 and 3 in rat tissues: Modulation by aging and differentiation in rat adipose tissue. J Mol Endocrinol 34: 153-161.
27. Sesti G, Tullio AN, D'Alfonso R, Napolitano ML, Marini MA, Borboni P, Longhi R, Albonici L, Fusco A, Agliano AM, et al., 1994. Tissue-specific expression of two alternatively spliced isoforms of the human insulin receptor protein. Acta Diabetol 31: 59-65.
28. Shojaee-Moradie F, Powrie JK, Sundermann E, Spring MW, Schuttler A, Sonksen PH, Brandenburg D, Jones RH,. 2000. Novel hepatoselective insulin analog: Studies with a covalently linked thyroxyl-insulin complex in humans. Diabetes Care 23: 1124-1129.
29. Sindelar DK, Balcom JH, Chu CA, Neal DW, Cherrington AD,. 1996. A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Diabetes 45: 1594-1604.
30. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD,. 1998. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 47: 523-529.
31. Stanley WC, Recchia FA, Lopaschuk GD,. 2005. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129.
32. Steil GM, Rebrin K, Mittelman SD, Bergman RN,. 1998. Role of portal insulin delivery in the disappearance of intravenous glucose and assessment of insulin sensitivity. Diabetes 47: 714-720.
33. Taniguchi CM, Emanuelli B, Kahn CR,. 2006. Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96.
34. Unger RH, Cherrington AD,. 2012. Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest 122: 4-12.
35. Ussar S, Vienberg SG, Kahn CR,. 2011. Receptor antibodies as novel therapeutics for diabetes. Sci Transl Med 3:113ps47.
36. Vugmeyster Y, DeFranco D, Szklut P, Wang Q, Xu X,. 2010. Biodistribution of [125I]-labeled therapeutic proteins: Application in protein drug development beyond oncology. J Pharm Sci 99: 1028-1045.
37. Wang W, Wang EQ, Balthasar JP,. 2008. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84: 548-558.
38. Yamaguchi Y, Flier JS, Yokota A, Benecke H, Backer JM, Moller DE,. 1991. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 129: 2058-2066.
39. Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, Reyes NA, Shen BQ, Fielder PJ, Prabhu S, Khawli LA, Boswell CA,. 2014. Quantitative cumulative biodistribution of antibodies in mice: Effect of modulating binding affinity to the neonatal Fc receptor. MAbs 6 (3): 689-96.
40. Zammit VA,. 1996. Role of insulin in hepatic fatty acid partitioning: Emerging concepts. Biochem J 314 (Pt 1): 1-14.